Vanguard Group Inc. Cuts Stock Holdings in Repligen Corporation (NASDAQ:RGEN)

Vanguard Group Inc. decreased its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 0.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,079,894 shares of the biotechnology company's stock after selling 21,196 shares during the period. Vanguard Group Inc. owned approximately 9.05% of Repligen worth $646,366,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raiffeisen Bank International AG acquired a new position in shares of Repligen during the fourth quarter worth approximately $29,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Repligen during the fourth quarter worth approximately $40,000. Signaturefd LLC increased its holdings in shares of Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 128 shares in the last quarter. Center for Financial Planning Inc. boosted its position in shares of Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 193 shares in the last quarter. Finally, UMB Bank n.a. lifted its position in Repligen by 99.4% in the 1st quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 332 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several research analyst reports. Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Barclays began coverage on shares of Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price target for the company. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 target price on the stock in a research note on Tuesday, July 22nd. HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a report on Monday, May 5th. Finally, Royal Bank Of Canada upped their target price on shares of Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a report on Wednesday, July 30th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and an average target price of $169.45.

Repligen Price Performance

Repligen stock traded down $2.29 during mid-day trading on Friday, reaching $124.35. 574,823 shares of the company's stock traded hands, compared to its average volume of 1,060,907. The company has a market cap of $7.00 billion, a price-to-earnings ratio of -497.38, a PEG ratio of 2.33 and a beta of 1.05. The stock has a 50 day moving average of $122.50 and a two-hundred day moving average of $132.99. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). The firm had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company's revenue was up 14.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.40 EPS. Equities analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Martin D. Madaus purchased 1,800 shares of the stock in a transaction dated Friday, August 8th. The shares were acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director owned 1,800 shares of the company's stock, valued at approximately $201,834. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.